Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation

Research output: Contribution to journalReview ArticleResearchpeer-review

5 Citations (Scopus)

Abstract

The metabotropic glutamate (mGlu) receptor family is a potential therapeutic target for multiple central nervous system (CNS) disorders. However, aspects of mGlu receptor signaling and their role in neural pathways remain to be fully elucidated. Novel subtype selective allosteric modulators have revealed new roles for mGlu receptors in brain health and disease, as well as expanding on previously underappreciated aspects of mGlu signaling such as biased agonism and modulation. Recent advances have improved our understanding of mGlu receptor function. Harnessing these new insights to inform drug discovery programs has the potential to lead to the design and discovery of mGlu allosteric modulators that specifically drive glutamatergic activity toward therapeutically beneficial effects and avoid on-target adverse effect liability.

Original languageEnglish
Pages (from-to)49-55
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume32
DOIs
Publication statusPublished - 1 Feb 2017

Cite this

@article{d1c08dcd18b945fba18a02e2231c3c3f,
title = "Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation",
abstract = "The metabotropic glutamate (mGlu) receptor family is a potential therapeutic target for multiple central nervous system (CNS) disorders. However, aspects of mGlu receptor signaling and their role in neural pathways remain to be fully elucidated. Novel subtype selective allosteric modulators have revealed new roles for mGlu receptors in brain health and disease, as well as expanding on previously underappreciated aspects of mGlu signaling such as biased agonism and modulation. Recent advances have improved our understanding of mGlu receptor function. Harnessing these new insights to inform drug discovery programs has the potential to lead to the design and discovery of mGlu allosteric modulators that specifically drive glutamatergic activity toward therapeutically beneficial effects and avoid on-target adverse effect liability.",
author = "Shane Hellyer and Katie Leach and Gregory, {Karen J}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.coph.2016.10.007",
language = "English",
volume = "32",
pages = "49--55",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier",

}

TY - JOUR

T1 - Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation

AU - Hellyer, Shane

AU - Leach, Katie

AU - Gregory, Karen J

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The metabotropic glutamate (mGlu) receptor family is a potential therapeutic target for multiple central nervous system (CNS) disorders. However, aspects of mGlu receptor signaling and their role in neural pathways remain to be fully elucidated. Novel subtype selective allosteric modulators have revealed new roles for mGlu receptors in brain health and disease, as well as expanding on previously underappreciated aspects of mGlu signaling such as biased agonism and modulation. Recent advances have improved our understanding of mGlu receptor function. Harnessing these new insights to inform drug discovery programs has the potential to lead to the design and discovery of mGlu allosteric modulators that specifically drive glutamatergic activity toward therapeutically beneficial effects and avoid on-target adverse effect liability.

AB - The metabotropic glutamate (mGlu) receptor family is a potential therapeutic target for multiple central nervous system (CNS) disorders. However, aspects of mGlu receptor signaling and their role in neural pathways remain to be fully elucidated. Novel subtype selective allosteric modulators have revealed new roles for mGlu receptors in brain health and disease, as well as expanding on previously underappreciated aspects of mGlu signaling such as biased agonism and modulation. Recent advances have improved our understanding of mGlu receptor function. Harnessing these new insights to inform drug discovery programs has the potential to lead to the design and discovery of mGlu allosteric modulators that specifically drive glutamatergic activity toward therapeutically beneficial effects and avoid on-target adverse effect liability.

UR - http://www.scopus.com/inward/record.url?scp=84994761123&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2016.10.007

DO - 10.1016/j.coph.2016.10.007

M3 - Review Article

VL - 32

SP - 49

EP - 55

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -